A Drug-Resistant Fungus Is Spreading Through American Hospitals

A drug-resistant fungus is quietly spreading through American hospitals at an alarming rate. Cases of Candida auris more than doubled between 2022 and 2024, according to new CDC data, raising urgent questions about infection control and the limits of modern medicine.

The Centers for Disease Control and Prevention (CDC) reported that Candida auris infections surged from approximately 2,300 cases in 2022 to more than 4,600 in 2024. This sharp rise has put healthcare facilities on high alert. Candida auris is a yeast that can cause severe bloodstream and wound infections, particularly in immunocompromised patients. What makes it especially dangerous is its resistance to multiple antifungal drugs, including fluconazole and amphotericin B. Some strains are even pan-resistant, meaning no existing antifungal can treat them.

The question on epidemiologists' minds is how much of this increase reflects true spread versus improved detection. Since 2021, the CDC has urged hospitals to screen high-risk patients more aggressively, and better testing may account for some of the rise. However, experts believe real transmission is accelerating, driven by lapses in hygiene, the reuse of medical equipment, and the movement of patients between long-term care facilities and acute-care hospitals.

The CDC's data shows that Candida auris is now endemic in at least 30 states, with hotspots in New York, Illinois, California, and Florida. The fungus can survive on surfaces for weeks and is easily spread via gloves, gowns, and shared devices like thermometers. Outbreaks have been linked to poor hand hygiene and inadequate disinfection protocols. In 2023, a Chicago hospital reported a cluster of 45 cases over six months, despite stringent cleaning efforts.

“We are seeing a perfect storm,” said Dr. Mariana Stevens, an infectious disease specialist at Johns Hopkins, in a recent presentation. “Antifungal resistance is evolving faster than our drug pipeline. Hospitals must double down on prevention.” The CDC has issued updated guidelines for screening, isolation, and surface decontamination, but implementation varies widely. Smaller rural hospitals often lack the resources and training to contain the pathogen.

The implications of this spread extend beyond individual hospitals. A pan-resistant fungus could become a global health crisis, especially in settings with limited testing capacity. The World Health Organization has listed Candida auris as a “critical priority” pathogen, urging nations to invest in surveillance and new therapies. However, only a handful of novel antifungals are in late-stage development, and none are expected to reach the market before 2028.

Looking ahead, experts predict cases will continue to rise as the population ages and more patients rely on invasive medical devices such as catheters and ventilators. The CDC plans to expand genomic surveillance to track mutations in real time. Hospitals are being urged to adopt “no-touch” disinfection technologies like UV light and hydrogen peroxide vapor. Patients and families can also play a role by asking about infection rates and insisting on hand hygiene. The silent spread of Candida auris is a stark reminder that antibiotic and antifungal resistance is one of the greatest public health threats of our time.